Biohaven Therapeutics Ltd.
BHV-7000
Focal Epilepsy
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for BHV-7000 in Focal Epilepsy are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06132893: Phase 3 trial, sponsor Biohaven Therapeutics Ltd., drug BHV-7000. Primary completion date 2026-12 (estimated).”